BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 31511295)

  • 1. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
    Fendler WP; Weber M; Iravani A; Hofman MS; Calais J; Czernin J; Ilhan H; Saad F; Small EJ; Smith MR; Perez PM; Hope TA; Rauscher I; Londhe A; Lopez-Gitlitz A; Cheng S; Maurer T; Herrmann K; Eiber M; Hadaschik B
    Clin Cancer Res; 2019 Dec; 25(24):7448-7454. PubMed ID: 31511295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
    Weber M; Fendler WP; Ravi Kumar AS; Calais J; Czernin J; Ilhan H; Saad F; Kretschmer A; Hekimsoy T; Brookman-May SD; Mundle SD; Small EJ; Smith MR; Perez PM; Hope TA; Herrmann K; Hofman MS; Eiber M; Hadaschik BA
    Eur Urol; 2024 Jun; 85(6):511-516. PubMed ID: 38490855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with
    Ferraro DA; Rüschoff JH; Muehlematter UJ; Kranzbühler B; Müller J; Messerli M; Husmann L; Hermanns T; Eberli D; Rupp NJ; Burger IA
    Theranostics; 2020; 10(14):6082-6094. PubMed ID: 32483440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
    Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
    Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial
    Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM
    J Nucl Med; 2019 Jul; 60(7):950-954. PubMed ID: 30552200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.
    Francolini G; Detti B; Bottero M; Zilli T; Lancia A; Bruni A; Borghesi S; Mariotti M; Castellucci P; Fanti S; Filippi AR; Teriaca MA; Maragna V; Aristei C; Mazzeo E; Livi L; Ingrosso G
    Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study.
    Weber M; Kurek C; Barbato F; Eiber M; Maurer T; Nader M; Hadaschik B; Grünwald V; Herrmann K; Wetter A; Fendler WP
    J Nucl Med; 2021 Jan; 62(1):88-91. PubMed ID: 32444377
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Akdemir EN; Tuncel M; Akyol F; Bilen CY; Baydar DE; Karabulut E; Ozen H; Caglar M
    World J Urol; 2019 May; 37(5):813-821. PubMed ID: 30151600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?
    Baboudjian M; Gauthé M; Barret E; Brureau L; Rocchi P; Créhange G; Dariane C; Fiard G; Fromont G; Beauval JB; Mathieu R; Renard-Penna R; Roubaud G; Ruffion A; Sargos P; Rouprêt M; Ploussard G
    Prog Urol; 2022 Jun; 32(6S1):6S43-6S53. PubMed ID: 36719646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Dietlein F; Mueller P; Kobe C; Endepols H; Hohberg M; Zlatopolskiy BD; Krapf P; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
    Mol Imaging Biol; 2021 Apr; 23(2):277-286. PubMed ID: 33006028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
    Xiang M; Ma TM; Savjani R; Pollom EL; Karnes RJ; Grogan T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Huland H; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; Rettig MB; Zaorsky NG; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D; Czernin J; Gafita A; Romero T; Calais J; Kishan AU
    JAMA Netw Open; 2021 Dec; 4(12):e2138550. PubMed ID: 34902034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Outcomes from
    Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
    J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
    [No Abstract]   [Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
    Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study.
    Farolfi A; Hirmas N; Gafita A; Weber M; Barbato F; Wetter A; Mei R; Pianori D; Hadaschik B; Herrmann K; Castellucci P; Fanti S; Eiber M; Fendler WP
    J Nucl Med; 2021 May; 62(5):675-678. PubMed ID: 32917782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Trial of
    Wang B; Liu C; Wei Y; Meng J; Zhang Y; Gan H; Xu X; Wan F; Pan J; Ma X; Hu S; Freedland SJ; Song S; Ye D; Zhu Y
    Clin Cancer Res; 2020 Sep; 26(17):4551-4558. PubMed ID: 32527944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.